You just read:

AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1

News provided by

AMO Pharma Limited

15 Mar, 2018, 18:32 GMT